Autolus Therapeutics plc (AUTL)
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Autolus Therapeutics plc
1-25 of 336 filings
Recent SEC filings with analysis
- 424B3Autolus Therapeutics filed a 424B3 prospectus registering the resale by Perceptive Credit Holdings V, LP of up to 3,500,000 ADSs issuable upon exercise of a…
- S-3Autolus Therapeutics filed an S-3 registration statement to register the resale by Perceptive Credit Holdings V, LP of up to 3,500,000 American Depositary…